seqid	type	start	end	name	nt_name	aa_name	vcf_gene	chrom_region	mutation_type	dp	ps_filter	ps_exc	mat_pep_id	mat_pep_desc	mat_pep_acc	ro	ao	reference_seq	variant_seq	viral_lineage	function_category	citation	comb_mutation	function_description	heterozygosity	clade_defining	who_label	variant	variant_status	voi_designation_date	voc_designation_date	alert_designation_date
MN908947.3	.	241	241	c.C-25T	c.C-25T		orf1ab	5' UTR		3271						2	3267	C	T	B.1.525					False	False	Eta	VOI	active	17-Mar-2021		
MN908947.3	.	1498	1498	p.F411F	c.C1233T	p.F411F	orf1ab	ORF1ab	SILENT	3279			nsp2	produced by both pp1a and pp1ab	YP_009725298.1	14	3264	C	T	B.1.525					False	False	Eta	VOI	active	17-Mar-2021		
MN908947.3	.	1807	1807	p.G514G	c.A1542G	p.G514G	orf1ab	ORF1ab	SILENT	3279			nsp2	produced by both pp1a and pp1ab	YP_009725298.1	11	3229	A	G	B.1.525					False	False	Eta	VOI	active	17-Mar-2021		
MN908947.3	.	2659	2659	p.K798K	c.G2394A	p.K798K	orf1ab	ORF1ab	SILENT	3279			nsp2	produced by both pp1a and pp1ab	YP_009725298.1	13	3264	G	A	B.1.525					False	False	Eta	VOI	active	17-Mar-2021		
MN908947.3	.	3037	3037	p.F924F	c.C2772T	p.F924F	orf1ab	ORF1ab	SILENT	3279			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab	YP_009725299.1	2	3277	C	T	B.1.525					False	False	Eta	VOI	active	17-Mar-2021		
MN908947.3	.	6285	6285	p.T2007I	c.C6020T	p.T2007I	orf1ab	ORF1ab	MISSENSE	3279			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab	YP_009725299.1	10	3263	C	T	B.1.525					False	True	Eta	VOI	active	17-Mar-2021		
MN908947.3	.	8593	8593	p.V2776V	c.T8328C	p.V2776V	orf1ab	ORF1ab	SILENT	3279			nsp4	nsp4B_TM, contains transmembrane domain 2 (TM2), produced by both pp1a and pp1ab	YP_009725300.1	2	3276	T	C	B.1.525					False	False	Eta	VOI	active	17-Mar-2021		
MN908947.3	.	9565	9565	p.F3100F	c.C9300T	p.F3100F	orf1ab	ORF1ab	SILENT	3279			nsp4	nsp4B_TM, contains transmembrane domain 2 (TM2), produced by both pp1a and pp1ab	YP_009725300.1	164	3073	C	T	B.1.525					False	False	Eta	VOI	active	17-Mar-2021		
MN908947.3	.	11287	11287	p.S3675_F3677del	c.11023_11031delTCTGGTTTT	p.S3675_F3677del	orf1ab	ORF1ab		3279			nsp6	nsp6_TM, putative transmembrane domain, produced by both pp1a and pp1ab	YP_009725302.1	3274	3177	GTCTGGTTTT	G	B.1.525					False	True	Eta	VOI	active	17-Mar-2021		
MN908947.3	.	11288	11288	p.S3675T	c.T11023A	p.S3675T	orf1ab	ORF1ab	MISSENSE	94			nsp6	nsp6_TM, putative transmembrane domain, produced by both pp1a and pp1ab	YP_009725302.1	23	56	T	N	B.1.525					False	False	Eta	VOI	active	17-Mar-2021		
MN908947.3	.	11289	11289	p.S3675Y	c.C11024A	p.S3675Y	orf1ab	ORF1ab	MISSENSE	94			nsp6	nsp6_TM, putative transmembrane domain, produced by both pp1a and pp1ab	YP_009725302.1	49	44	C	N	B.1.525					False	False	Eta	VOI	active	17-Mar-2021		
MN908947.3	.	11291	11291	p.G3676S	c.G11026A	p.G3676S	orf1ab	ORF1ab	MISSENSE	98			nsp6	nsp6_TM, putative transmembrane domain, produced by both pp1a and pp1ab	YP_009725302.1	17	25	G	N	B.1.525					False	False	Eta	VOI	active	17-Mar-2021		
MN908947.3	.	11291	11291	p.G3676S	c.G11026A	p.G3676S	orf1ab	ORF1ab	MISSENSE	98			nsp6	nsp6_TM, putative transmembrane domain, produced by both pp1a and pp1ab	YP_009725302.1	17	55	G	A	B.1.525					False	False	Eta	VOI	active	17-Mar-2021		
MN908947.3	.	11296	11296	p.F3677L	c.T11031G	p.F3677L	orf1ab	ORF1ab	MISSENSE	99			nsp6	nsp6_TM, putative transmembrane domain, produced by both pp1a and pp1ab	YP_009725302.1	13	65	T	G	B.1.525					False	False	Eta	VOI	active	17-Mar-2021		
MN908947.3	.	14407	14407	p.P4715S	c.C14143T	p.P4715S	orf1ab	ORF1ab	MISSENSE	3279						9	3269	C	T	B.1.525					False	False	Eta	VOI	active	17-Mar-2021		
MN908947.3	.	14408	14408	p.P4715L	c.C14144T	p.P4715L	orf1ab	ORF1ab	MISSENSE	3279						4	3274	C	T	B.1.525					False	False	Eta	VOI	active	17-Mar-2021		
MN908947.3	.	18171	18171	p.G5969G	c.C17907T	p.G5969G	orf1ab	ORF1ab	SILENT	3279			3'-to-5' exonuclease	nsp14A2_ExoN and nsp14B_NMT, produced by pp1ab only	YP_009725309.1	6	3269	C	T	B.1.525					False	False	Eta	VOI	active	17-Mar-2021		
MN908947.3	.	20724	20724	p.L6820L	c.A20460G	p.L6820L	orf1ab	ORF1ab	SILENT	3279			2'-O-ribose methyltransferase	nsp16_OMT, 2'-o-MT, produced by pp1ab only	YP_009725311.1	10	3267	A	G	B.1.525					False	False	Eta	VOI	active	17-Mar-2021		
MN908947.3	.	21717	21717	p.Q52R	c.A155G	p.Q52R	S	S	MISSENSE	3279						54	2561	A	G	B.1.525	transmissibility	Albertsen et al. (2021) 		The B.1.525 appears to have poor transmissibility when in competition with B.1.1.7 and other cirdulting strains in Denmark (early 2021).	False	True	Eta	VOI	active	17-Mar-2021		
MN908947.3	.	21764	21764	p.H69_V70del	c.203_208delTACATG	p.H69_V70del	S	S		3279						3254	3180	ATACATG	A	B.1.525					False	True	Eta	VOI	active	17-Mar-2021		
MN908947.3	.	21765	21765	p.I68K	c.T203A	p.I68K	S	S	MISSENSE	91						59	32	T	N	B.1.525					False	False	Eta	VOI	active	17-Mar-2021		
MN908947.3	.	21766	21766	p.I68M	c.A204G	p.I68M	S	S	MISSENSE	89						42	38	A	N	B.1.525					False	False	Eta	VOI	active	17-Mar-2021		
MN908947.3	.	21767	21767	p.H69N	c.C205A	p.H69N	S	S	MISSENSE	88						39	47	C	N	B.1.525					False	False	Eta	VOI	active	17-Mar-2021		
MN908947.3	.	21768	21768	p.H69P	c.A206C	p.H69P	S	S	MISSENSE	95						39	43	A	N	B.1.525					False	False	Eta	VOI	active	17-Mar-2021		
MN908947.3	.	21769	21769	p.H69Q	c.T207A	p.H69Q	S	S	MISSENSE	96						50	46	T	N	B.1.525					False	False	Eta	VOI	active	17-Mar-2021		
MN908947.3	.	21770	21770	p.V70I	c.G208A	p.V70I	S	S	MISSENSE	97						40	46	G	N	B.1.525					False	False	Eta	VOI	active	17-Mar-2021		
MN908947.3	.	21990	21990	p.Y144del	c.429_431delTTA	p.Y144del	S	S		3279						3253	3082	TTTA	T	B.1.525	immunosuppression variant emergence	Avanzato et al. (2020) 		Emergent as 100% variant from larger minor (1% allele frequency) deletion by day 70 post-infection of female immunocompromised  individual with chronic lymphocytic leukemia and acquired hypogammaglobulinemia. Variant disappeared after convalescent plasma treatment (day 71) in subsequent sample sequencing.	False	False	Eta	VOI	active	17-Mar-2021		
MN908947.3	.	21990	21990	p.Y144del	c.429_431delTTA	p.Y144del	S	S		3279						3253	3082	TTTA	T	B.1.525	antibody epitope effects	Haynes et al. (2021) 		Wildtype elicits immune response, COVID-19 cohort epitope score > 99th percentile of the 497 pre-pandemic controls, mutant drops PIWAS epitope score from 1% to 0.17% (poorer immune recognition) Together with other B1.1.7 lineage mutational changes (Spike: N501Y, A570D, P681H, Nucleoprotein: D3L, S235F) resulted in only 2 of 579 individuals (0.3% of the population) having a dramatic reduction in PIWAS antigen scores, which reflects the peak epitope signal along the entire antigen. 	False	False	Eta	VOI	active	17-Mar-2021		
MN908947.3	.	21990	21990	p.Y144del	c.429_431delTTA	p.Y144del	S	S		3279						3253	3082	TTTA	T	B.1.525	antibody epitope effects	McCallum et al. (2021) 		"Massive reduction in S2M28 monoclonal antibody EC50 (i.e. ablated recognition), within antigenic supersite ""i""  Massive reduction in S2X28 monoclonal antibody EC50 (i.e. ablated recognition), within antigenic supersite ""i""  Massive reduction in S2X333 monoclonal antibody EC50 (i.e. ablated recognition), within antigenic supersite ""i""  Massive reduction in 4A8 monoclonal antibody EC50 (i.e. ablated recognition) "	False	False	Eta	VOI	active	17-Mar-2021		
MN908947.3	.	21990	21990	p.Y144del	c.429_431delTTA	p.Y144del	S	S		3279						3253	3082	TTTA	T	B.1.525	antibody epitope effects	Wang et al. (2021) 		Abolishes neutralization by N-terminal-domain-directed mAbs 5-24, 4-8, and 4A8.	False	False	Eta	VOI	active	17-Mar-2021		
MN908947.3	.	21990	21990	p.Y144del	c.429_431delTTA	p.Y144del	S	S		3279						3253	3082	TTTA	T	B.1.525	trafficking	Tada et al. (2021) 		Lentiviral pseudotyped with this individual mutation from B.1.1.7 was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing slightly increased infection rate amongst the cells. 	False	False	Eta	VOI	active	17-Mar-2021		
MN908947.3	.	21990	21990	p.Y144del	c.429_431delTTA	p.Y144del	S	S		3279						3253	3082	TTTA	T	B.1.525	convalescent plasma escape	McCarthy et al. (2021) 		Virus evolution data in 9 immunocomprised patients with long active COVID-19 infections was gathered, showing sequence deletion hotspots. This variant was present in 4 patients.	False	False	Eta	VOI	active	17-Mar-2021		
MN908947.3	.	21991	21991	p.V143V	c.T429A	p.V143V	S	S	SILENT	195						62	133	T	N	B.1.525					False	False	Eta	VOI	active	17-Mar-2021		
MN908947.3	.	21992	21992	p.Y144N	c.T430A	p.Y144N	S	S	MISSENSE	195						51	138	T	N	B.1.525	monoclonal antibody serial passage escape	McCallum et al. (2021) 		Escape mutation against Spike N terminal domain antigenic supersite i mAb S2X28	False	False	Eta	VOI	active	17-Mar-2021		
MN908947.3	.	21993	21993	p.Y144S	c.A431C	p.Y144S	S	S	MISSENSE	191						45	134	A	N	B.1.525					False	False	Eta	VOI	active	17-Mar-2021		
MN908947.3	.	23012	23012	p.E484K	c.G1450A	p.E484K	S	S	MISSENSE	3279						9	3269	G	A	B.1.525	T cell evasion	Reynolds et al. (2021) 		Analyzing responses to the E484K mutation seen in B.1.351 and P.1 variants, we noted that it did  not fall in a region predicted to bind the HLAII alleles tested (table S4). The mutation appeared  to have no substantial or differential impact on T cell responses.	False	True	Eta	VOI	active	17-Mar-2021		
MN908947.3	.	23012	23012	p.E484K	c.G1450A	p.E484K	S	S	MISSENSE	3279						9	3269	G	A	B.1.525	antibody epitope effects	Sun et al. (2021) 		Complete loss of binding in ELISA by the variant against monoclonal antibody VH-Fc ab8	False	True	Eta	VOI	active	17-Mar-2021		
MN908947.3	.	23012	23012	p.E484K	c.G1450A	p.E484K	S	S	MISSENSE	3279						9	3269	G	A	B.1.525	antibody epitope effects	Collier et al. (2021) 		Of 50 mAbs tested, major loss of neutralization observed for S2N28, S2X615, S2N12, S2X192, S2H7, S2X16, S2X58, S2H70, S2X613, S2D19, S2N22, S2D32, S2H58, S2M11, S2D106, S2X30.	False	True	Eta	VOI	active	17-Mar-2021		
MN908947.3	.	23012	23012	p.E484K	c.G1450A	p.E484K	S	S	MISSENSE	3279						9	3269	G	A	B.1.525	antibody epitope effects	Li et al. (2021) 		Monoclonal antibodies 13G9 and 58G6 maintain fairly high neutralization potency, compared to others interfacing with E484K.	False	True	Eta	VOI	active	17-Mar-2021		
MN908947.3	.	23012	23012	p.E484K	c.G1450A	p.E484K	S	S	MISSENSE	3279						9	3269	G	A	B.1.525	antibody epitope effects	Wibmer et al. (2021) 		"Ablates ELISA test binding for class 1 (Spike 'up' conformation only, RBD targeting) monoclonal antibody CA1 on 501Y.V2 (""South African"") lineage background  Ablates ELISA test binding for class 1 (Spike 'up' conformation only, RBD targeting) monoclonal antibody LyCoV016 (also known as CB6 or JS016) on 501Y.V2 (""South African"") lineage background Ablates ELISA test binding for class 1 (Spike 'up' conformation only, RBD targeting) monoclonal antibody CC12.1 on 501Y.V2 (""South African"") lineage background Ablates ELISA test binding for class 2 (Spike 'up' or 'down' conformation, RBD targeting) monoclonal antibody BD23 on 501Y.V2 (""South African"") lineage background  Ablates ELISA test binding for class 2 (Spike 'up' or 'down' conformation, RBD targeting) monoclonal antibody C119 (also known as CB6 or JS016) on 501Y.V2 (""South African"") lineage background Ablates ELISA test binding for class 2 (Spike 'up' or 'down' conformation, RBD targeting) monoclonal antibody P2B-2F6 on 501Y.V2 (""South African"") lineage background"	False	True	Eta	VOI	active	17-Mar-2021		
MN908947.3	.	23012	23012	p.E484K	c.G1450A	p.E484K	S	S	MISSENSE	3279						9	3269	G	A	B.1.525	antibody epitope effects	Chen et al. (2021) 		Ablates Class 1 receptor-binding-motif targeting antibodies COV2-2050, 1B07, COVOX-384, and S2H58.	False	True	Eta	VOI	active	17-Mar-2021		
MN908947.3	.	23012	23012	p.E484K	c.G1450A	p.E484K	S	S	MISSENSE	3279						9	3269	G	A	B.1.525	antibody epitope effects	Chen et al. (2021) 		Ablates Class 1 receptor-binding-motif targeting antibodies COV2-2050, 1B07, COVOX-384, and S2H58. Ablates Class 3 N-terminal domain targeting antibody COV2-2489, diminishes COV2-2676.	False	True	Eta	VOI	active	17-Mar-2021		
MN908947.3	.	23012	23012	p.E484K	c.G1450A	p.E484K	S	S	MISSENSE	3279						9	3269	G	A	B.1.525	antibody epitope effects	Gaebler et al. (2021) 		Ablates binding by class 2 mAbs such as C144 that directly interfere with ACE2 binding,  but clonal somatic mutations of memory B cells at 6.2 months (evolving humoral immune response)  show pronounced increase in binding to the variant. 	False	True	Eta	VOI	active	17-Mar-2021		
MN908947.3	.	23012	23012	p.E484K	c.G1450A	p.E484K	S	S	MISSENSE	3279						9	3269	G	A	B.1.525	antibody epitope effects	Liu et al. (2020) 		Mutant screen in neutralization assay with a broad range of monoclonal antibodies shows high resistence to 4 antibodies,  and broad low level resistence against much of the rest of the panel.	False	True	Eta	VOI	active	17-Mar-2021		
MN908947.3	.	23012	23012	p.E484K	c.G1450A	p.E484K	S	S	MISSENSE	3279						9	3269	G	A	B.1.525	antibody epitope effects	Wang et al. (2021) 		Resistent to all seven class 2 (Spike 'up' or 'down' conformation, RBD targeting) antibodies tested, with 10-fold  or greater reduction in neutralization (plus notable reudction in two unclassfied mAbs).	False	True	Eta	VOI	active	17-Mar-2021		
MN908947.3	.	23012	23012	p.E484K	c.G1450A	p.E484K	S	S	MISSENSE	3279						9	3269	G	A	B.1.525	antibody epitope effects	Chen et al. (2021) 		Ablates Class 1 receptor-binding-motif targeting antibodies COV2-2050, 1B07, COVOX-384 and S2H58.	False	True	Eta	VOI	active	17-Mar-2021		
MN908947.3	.	23012	23012	p.E484K	c.G1450A	p.E484K	S	S	MISSENSE	3279						9	3269	G	A	B.1.525	antibody epitope effects	Wang et al. (2021) 		Pseudotyped virus model ablates neutralization by RBD-directed mAbs 4-20, 2-4, 2-43, 2-30, 2-15, LY-Cov555, C121. Pseudotyped virus model impairs neutralization by RBD-directed mAb COV2-2196 (somewhat more than fully pseudotyped B.1.351 or live virus)	False	True	Eta	VOI	active	17-Mar-2021		
MN908947.3	.	23012	23012	p.E484K	c.G1450A	p.E484K	S	S	MISSENSE	3279						9	3269	G	A	B.1.525	antibody epitope effects	Rappazzo et al. (2021) 		Massive reduction in binding efficiency vs wild type for mAb LY-CoV555.	False	True	Eta	VOI	active	17-Mar-2021		
MN908947.3	.	23012	23012	p.E484K	c.G1450A	p.E484K	S	S	MISSENSE	3279						9	3269	G	A	B.1.525	ACE2 receptor binding affinity	Liu et al. (2021) 		Studying the key covariants in lineage of concern 501Y.V2,  observed about 2-fold increase in ACE2 binding vs wildtype, but greatly decreased mAb binding, suggesting evolutionary optimum tension between  immune evasion and ACE2 binding affinity as the N501Y variant alone has 10x increase in affinity but no effect on tested mAb binding.	False	True	Eta	VOI	active	17-Mar-2021		
MN908947.3	.	23012	23012	p.E484K	c.G1450A	p.E484K	S	S	MISSENSE	3279						9	3269	G	A	B.1.525	ACE2 receptor binding affinity	Tian et al. (2021) 		Reported slight increase in affinity compared to wild-type RBD on the cell surface (Kd 	False	True	Eta	VOI	active	17-Mar-2021		
MN908947.3	.	23012	23012	p.E484K	c.G1450A	p.E484K	S	S	MISSENSE	3279						9	3269	G	A	B.1.525	ACE2 receptor binding affinity	Vogel et al. (2021) 		The affinity of ACE2 for this mutation combination was twice as high as for wild type. Having in mind that the affinity of SARS-CoV-2 for ACE2 is only 4-fold higher compared to SARS-CoV-1, this factor of 2 is expected to be biologically significant.	False	True	Eta	VOI	active	17-Mar-2021		
MN908947.3	.	23012	23012	p.E484K	c.G1450A	p.E484K	S	S	MISSENSE	3279						9	3269	G	A	B.1.525	ACE2 receptor binding affinity	Laffeber et al. (2021) 		RBD containing the N501Y mutation results in 9-fold stronger binding to the hACE2 receptor than  wild type RBD. The E484K mutation does not significantly influence the affinity for the receptor,  while K417N attenuates affinity. As a result, RBD from B.1.351 containing all three mutations binds  3-fold stronger to hACE2 than wild type RBD but 3-fold weaker than N501Y.	False	True	Eta	VOI	active	17-Mar-2021		
MN908947.3	.	23012	23012	p.E484K	c.G1450A	p.E484K	S	S	MISSENSE	3279						9	3269	G	A	B.1.525	ACE2 receptor binding affinity	Ramanathan et al. (2021) 		Using Mircoscale Thermopheresis, the B.1.351 variant harboring three mutations, binds ACE2 at nearly  five-fold greater affinity than the original SARS-COV-2 RBD (Kd 87.6, vs 402.5 nM).	False	True	Eta	VOI	active	17-Mar-2021		
MN908947.3	.	23012	23012	p.E484K	c.G1450A	p.E484K	S	S	MISSENSE	3279						9	3269	G	A	B.1.525	ACE2 receptor binding affinity	Collier et al. (2021) 		This combination showed ~3x increase binding to ACE2 vs wild type, about half that of the B.1.1.7 lineage, suggesting that the K417N mutation is slightly detrimental to ACE2 binding, probably as a result of disrupting the salt bridge formed with ACE2 residue D30	False	True	Eta	VOI	active	17-Mar-2021		
MN908947.3	.	23012	23012	p.E484K	c.G1450A	p.E484K	S	S	MISSENSE	3279						9	3269	G	A	B.1.525	ACE2 receptor binding affinity	Tian et al. (2021) 		Reported moderate increase in affinity compared to wild-type RBD on the cell surface (Kd 	False	True	Eta	VOI	active	17-Mar-2021		
MN908947.3	.	23012	23012	p.E484K	c.G1450A	p.E484K	S	S	MISSENSE	3279						9	3269	G	A	B.1.525	ACE2 receptor binding affinity	Zahradnik et al. (2021) 		Among the first selected variants in an in vitro evolution experiment for ACE2 binding.	False	True	Eta	VOI	active	17-Mar-2021		
MN908947.3	.	23012	23012	p.E484K	c.G1450A	p.E484K	S	S	MISSENSE	3279						9	3269	G	A	B.1.525	ACE2 receptor binding affinity	Starr et al. (2020) 		Experimentally, ACE2 binding affinity increased 0.06 fold	False	True	Eta	VOI	active	17-Mar-2021		
MN908947.3	.	23012	23012	p.E484K	c.G1450A	p.E484K	S	S	MISSENSE	3279						9	3269	G	A	B.1.525	trafficking	Kuzmina et al. (2021) 	'D614G'	~2x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction.	False	True	Eta	VOI	active	17-Mar-2021		
MN908947.3	.	23012	23012	p.E484K	c.G1450A	p.E484K	S	S	MISSENSE	3279						9	3269	G	A	B.1.525	trafficking	Ferriera et al (2021) 		This variant alone shows a ~5x decrease in cell entry efficiency (RLU measurement in 293T cells) compared to D614G. 	False	True	Eta	VOI	active	17-Mar-2021		
MN908947.3	.	23012	23012	p.E484K	c.G1450A	p.E484K	S	S	MISSENSE	3279						9	3269	G	A	B.1.525	trafficking	Tada et al. (2021) 		Lentiviral pseudotyped with this individual mutation from B.1.351 was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing no change in infection rate amongst the cells.	False	True	Eta	VOI	active	17-Mar-2021		
MN908947.3	.	23012	23012	p.E484K	c.G1450A	p.E484K	S	S	MISSENSE	3279						9	3269	G	A	B.1.525	pharmaceutical effectiveness	Liu et al. (2021) 		This mutated version of RBD completely abolishes the binding to a therapeutic antibody, Bamlanivimab, in vitro.	False	True	Eta	VOI	active	17-Mar-2021		
MN908947.3	.	23012	23012	p.E484K	c.G1450A	p.E484K	S	S	MISSENSE	3279						9	3269	G	A	B.1.525	pharmaceutical effectiveness	Engelhart et al. (2021) 		Tixagevimab, Regdanvimab and COR-101 display reduced binding affinity to virus pseudotyped as RBD from B.1.351.	False	True	Eta	VOI	active	17-Mar-2021		
MN908947.3	.	23012	23012	p.E484K	c.G1450A	p.E484K	S	S	MISSENSE	3279						9	3269	G	A	B.1.525	pharmaceutical effectiveness	Engelhart et al. (2021) 		Bamlanivimab (LY-CoV555) lost ~16x binding against this isolated mutation. Casirivimab lost ~16x binding against this isolated mutation.	False	True	Eta	VOI	active	17-Mar-2021		
MN908947.3	.	23012	23012	p.E484K	c.G1450A	p.E484K	S	S	MISSENSE	3279						9	3269	G	A	B.1.525	convalescent plasma escape	Tada et al. (2021) 	'D614G'	Pseudotyped viruses for B.1.618 was 2.5-fold resistant to neutralization by convalescent sera compared to wild type - a finding that was similar to that of the 3-fold resistance of the South Africa B.1.351 variant using the same assay. The resistance of B.1.618 was caused by the E484K mutation, based on results from viruses pseudotyped for individual variants within B.1.618. [details on the convalescent patient sera collection are not abundantly clear in the preprint]	False	True	Eta	VOI	active	17-Mar-2021		
MN908947.3	.	23012	23012	p.E484K	c.G1450A	p.E484K	S	S	MISSENSE	3279						9	3269	G	A	B.1.525	convalescent plasma escape	Tang et al. (2021) 		As measured by surface plasmon resonance, RBD with the E484K mutation alone showed a mean 19.1x decrease in binding affinity for  six batches of hyperimmune immunoglobulin (hCoV-2IG) preparations generated from SARS-CoV-2 convalescent plasma.	False	True	Eta	VOI	active	17-Mar-2021		
MN908947.3	.	23012	23012	p.E484K	c.G1450A	p.E484K	S	S	MISSENSE	3279						9	3269	G	A	B.1.525	convalescent plasma escape	Tada et al. (2021) 		The only mutation in the B.1.351 lineage that appears to contribute to neutralization reduction (~1.7x across 10 convalescent sera from April 2020 infectees)	False	True	Eta	VOI	active	17-Mar-2021		
MN908947.3	.	23012	23012	p.E484K	c.G1450A	p.E484K	S	S	MISSENSE	3279						9	3269	G	A	B.1.525	convalescent plasma escape	Alenquer et al. (2021) 		Average ~5-fold reduction in neutralization efficacy in convalescent sera of 16 health workers infected in Spring 2020.	False	True	Eta	VOI	active	17-Mar-2021		
MN908947.3	.	23012	23012	p.E484K	c.G1450A	p.E484K	S	S	MISSENSE	3279						9	3269	G	A	B.1.525	convalescent plasma escape	Zhou et al. (2021) 		"Subtype of the B.1.526 ""New York"" lineage, lentivirus pseudotyped with this mutation combination in showed 3.3x reduction in  IC50 serum dilution concentration for 6 convalescent sera."	False	True	Eta	VOI	active	17-Mar-2021		
MN908947.3	.	23012	23012	p.E484K	c.G1450A	p.E484K	S	S	MISSENSE	3279						9	3269	G	A	B.1.525	convalescent plasma escape	Liu et al. (2021) 		Remarkably, several of the E484 escape mutants were resistant to neutralization at the highest concentration (1:80 initial dilution) of all 4 convalescent sera tested (triplicate experiments). Against a wider panel of 16 convalescent plasma (no replicates), all but one show major resistance.	False	True	Eta	VOI	active	17-Mar-2021		
MN908947.3	.	23012	23012	p.E484K	c.G1450A	p.E484K	S	S	MISSENSE	3279						9	3269	G	A	B.1.525	convalescent plasma escape	Wang et al. (2021) 		The neutralizing activity of 15/20 convalescent sera was significantly lower against this pseudotyped virus model	False	True	Eta	VOI	active	17-Mar-2021		
MN908947.3	.	23012	23012	p.E484K	c.G1450A	p.E484K	S	S	MISSENSE	3279						9	3269	G	A	B.1.525	convalescent plasma escape	Wibmer et al. (2021) 		"Nearly half (21 of 44, 48%) of early pandemic exposure convalescent plasma/sera failed to neutralize the 501Y.V2 (""South African"") lineage pseudovirus construct Only 3 of 44 convascent sera (those with the highest titer, which correlated direectly with initial infection severity) had high neutralization against this 501Y.V2  PG: note that lineage variant R246I was excluded from the text in reference to these sera assays, not sure if that was an oversight."	False	True	Eta	VOI	active	17-Mar-2021		
MN908947.3	.	23012	23012	p.E484K	c.G1450A	p.E484K	S	S	MISSENSE	3279						9	3269	G	A	B.1.525	convalescent plasma escape	Cele et al. (2021) 		The 501Y.V2 to first wave IC50 ratio ranged from 6 to 200-fold. Averaging across all 7 participant convalescent sera highlighted the dramatic decrease in sensitivity to neutralization of authentic 501Y.V2 variants. PG: I'm purposefully ignoring D614G and A701V as contributors	False	True	Eta	VOI	active	17-Mar-2021		
MN908947.3	.	23012	23012	p.E484K	c.G1450A	p.E484K	S	S	MISSENSE	3279						9	3269	G	A	B.1.525	convalescent plasma escape	Wibmer et al. (2021) 		"27% of 44 early pandemic exposure convalescent plasma/sera lose all activity against a RBD triple mutant pseudovirus (RBD mutatants of the 501Y.V2 ""South African"" lineage), while only 23% retained high titres "	False	True	Eta	VOI	active	17-Mar-2021		
MN908947.3	.	23012	23012	p.E484K	c.G1450A	p.E484K	S	S	MISSENSE	3279						9	3269	G	A	B.1.525	convalescent plasma escape	Andreano et al. (2020) 		This mutation occurred in 100% of sequenced virions after 12 passages and led to a 4-fold decrease in convalescent plasma neutralization activity	False	True	Eta	VOI	active	17-Mar-2021		
MN908947.3	.	23012	23012	p.E484K	c.G1450A	p.E484K	S	S	MISSENSE	3279						9	3269	G	A	B.1.525	transmissibility	Albertsen et al. (2021) 		The B.1.525 appears to have poor transmissibility when in competition with B.1.1.7 and other cirdulting strains in Denmark (early 2021).	False	True	Eta	VOI	active	17-Mar-2021		
MN908947.3	.	23012	23012	p.E484K	c.G1450A	p.E484K	S	S	MISSENSE	3279						9	3269	G	A	B.1.525	vaccine neutralization efficacy	Tada et al. (2021) 	'D614G'	Pseudotyped viruses for B.1.618 was 2.7-fold resistant to neutralization by 6 BNT162b2 vaccine sera 28 days post-booster compared to wild type - a finding that was similar to that of the 3.4-fold resistance of the South Africa B.1.351 variant using the same assay. Neutralization by 3 Moderna vaccine sera 28 days post-booster was 3-fold resistant (vs. 2.2-fold for B.1.351). The resistance of B.1.618 was caused by the E484K mutation, based on results from viruses pseudotyped for individual variants within B.1.618.	False	True	Eta	VOI	active	17-Mar-2021		
MN908947.3	.	23012	23012	p.E484K	c.G1450A	p.E484K	S	S	MISSENSE	3279						9	3269	G	A	B.1.525	vaccine neutralization efficacy	Solfrosi et al. (2021) 		Neutralizing antibody titers of non-human primate sera after one or two doses of Ad26.COV2.S (Jannsen vaccine)  against the variants containing the E484K substitution in the RBD were present but reduced  (fold reduction between 3.35–7.78, 95% confidence interval all above twofold difference, one-sample t test). 	False	True	Eta	VOI	active	17-Mar-2021		
MN908947.3	.	23012	23012	p.E484K	c.G1450A	p.E484K	S	S	MISSENSE	3279						9	3269	G	A	B.1.525	vaccine neutralization efficacy	Ikegame et al. (2021) 		E484K pseudotyped VSV was tested for neutralization in a clonal HEK-293T ACE2 TMPRSS2 cell line optimized for highly efficient  S-mediated infection. A cohort of 12 Argentinian recipients of the Gamaleya Sputnik V Ad26 / Ad5 vaccine  showed a mean 2.8x decrease in neutralization effiacacy.	False	True	Eta	VOI	active	17-Mar-2021		
MN908947.3	.	23012	23012	p.E484K	c.G1450A	p.E484K	S	S	MISSENSE	3279						9	3269	G	A	B.1.525	vaccine neutralization efficacy	Jangra et al. (2021) 		Human sera from 5 two-dose Pfizer vaccinated individuals (47-68 days post 1st-dose) neutralized this variant 3.4x less relative to reference  USA-WA1/2020 strain. 8 convalescent plasma with weak IgG ELISA titre neutralized this variant 2.4x less relative to reference  USA-WA1/2020 strain. One plasma failed to neutralize at all. 11 convalescent plasma with moderate IgG ELISA titre neutralized this variant 4.2x less relative to reference  USA-WA1/2020 strain.  11 convalescent plasma with high IgG ELISA titre neutralized this variant 2.6x less relative to reference  USA-WA1/2020 strain. 	False	True	Eta	VOI	active	17-Mar-2021		
MN908947.3	.	23012	23012	p.E484K	c.G1450A	p.E484K	S	S	MISSENSE	3279						9	3269	G	A	B.1.525	vaccine neutralization efficacy	Kuzmina et al. (2021) 	'D614G'	This variant showed only minor in Pfizer sera (one or two dose) neutralization efficiency vs D614G (using lentivirus pseudotype).	False	True	Eta	VOI	active	17-Mar-2021		
MN908947.3	.	23012	23012	p.E484K	c.G1450A	p.E484K	S	S	MISSENSE	3279						9	3269	G	A	B.1.525	vaccine neutralization efficacy	Ferreira et al. (2021) 		Nine stored sera from Pfizer BNT162b2 vaccinees were tested against a range of spike mutation bearing PV. E484K conferred a ten-fold reduction in neutralisation by vaccine sera.	False	True	Eta	VOI	active	17-Mar-2021		
MN908947.3	.	23012	23012	p.E484K	c.G1450A	p.E484K	S	S	MISSENSE	3279						9	3269	G	A	B.1.525	vaccine neutralization efficacy	Wang et al. (2021) 		In a cohort of 20 patients 8+ weeks after second vaccine dose of Moderna (mRNA-1273) or Pfizer-BioNTech (BNT162b2) vaccines,  ELISA tests show 10x reduced efficacy of a majority of isolated antibodies, but only a modest decrease for vaccine plasma overall.	False	True	Eta	VOI	active	17-Mar-2021		
MN908947.3	.	23012	23012	p.E484K	c.G1450A	p.E484K	S	S	MISSENSE	3279						9	3269	G	A	B.1.525	monoclonal antibody serial passage escape	Liu et al. (2021) 		In serial experiment of mAb 2B04 resistent mutation isolate E48K then selected against mAb 2H04, this combination caused escape from both mAbs, even though incubation simultaneously with both mAbs failed to yield this combination.	False	True	Eta	VOI	active	17-Mar-2021		
MN908947.3	.	23012	23012	p.E484K	c.G1450A	p.E484K	S	S	MISSENSE	3279						9	3269	G	A	B.1.525	monoclonal antibody serial passage escape	Liu et al. (2021) 		In serial experiment of mAb 2B04 resistent mutation isolate E48K then selected against mAb 2H04, this combination caused escape from both mAbs, even though incubation simultaneously with both mAbs failed to yield this combination.	False	True	Eta	VOI	active	17-Mar-2021		
MN908947.3	.	23012	23012	p.E484K	c.G1450A	p.E484K	S	S	MISSENSE	3279						9	3269	G	A	B.1.525	monoclonal antibody serial passage escape	Liu et al. (2021) 		In serial experiment of mAb 2B04 resistent mutation isolate E48K then selected against mAb 2H04, this combination caused escape from both mAbs, even though incubation simultaneously with both mAbs failed to yield this combination.	False	True	Eta	VOI	active	17-Mar-2021		
MN908947.3	.	23012	23012	p.E484K	c.G1450A	p.E484K	S	S	MISSENSE	3279						9	3269	G	A	B.1.525	monoclonal antibody serial passage escape	Liu et al. (2021) 		In serial experiment of mAb 2B04 resistent mutation isolate E48K then selected against mAb 2H04, this combination caused escape from both mAbs, even though incubation simultaneously with both mAbs failed to yield this combination.	False	True	Eta	VOI	active	17-Mar-2021		
MN908947.3	.	23012	23012	p.E484K	c.G1450A	p.E484K	S	S	MISSENSE	3279						9	3269	G	A	B.1.525	monoclonal antibody serial passage escape	Liu et al. (2021) 		In serial experiment of mAb 2B04 resistent mutation isolate E48K then selected against mAb 2H04, this combination caused escape from both mAbs, even though incubation simultaneously with both mAbs failed to yield this combination.	False	True	Eta	VOI	active	17-Mar-2021		
MN908947.3	.	23012	23012	p.E484K	c.G1450A	p.E484K	S	S	MISSENSE	3279						9	3269	G	A	B.1.525	monoclonal antibody serial passage escape	Baum et al. (2020) 		Escape variant 100% appearance in 2 passages against Regeneron monoclonal antibody REGN10989 @ 50ug/mL (99% after one passage)	False	True	Eta	VOI	active	17-Mar-2021		
MN908947.3	.	23012	23012	p.E484K	c.G1450A	p.E484K	S	S	MISSENSE	3279						9	3269	G	A	B.1.525	monoclonal antibody serial passage escape	Weisblum et al. (2020) 		Strong positive selection (up to 50% of supernatant sequences) after C121 monoclonal antibody assay, decreasing in subsequent passages Strong positive selection (up to 44% of supernatant sequences) after after one round of C144 monoclonal antibody passage, then waning on subsequent passages	False	True	Eta	VOI	active	17-Mar-2021		
MN908947.3	.	23012	23012	p.E484K	c.G1450A	p.E484K	S	S	MISSENSE	3279						9	3269	G	A	B.1.525	monoclonal antibody serial passage escape	Barnes et al. (2020) 		The engineered mutation cause 10-fold or more increase in the disassociation constant with many monoclonal antibodies (C144/C002/C121/C104/C110).	False	True	Eta	VOI	active	17-Mar-2021		
MN908947.3	.	23012	23012	p.E484K	c.G1450A	p.E484K	S	S	MISSENSE	3279						9	3269	G	A	B.1.525	monoclonal antibody serial passage escape	Greaney et al. (2020) 		Mildly effective mutant against this position in the RBD for highly neutralizing COV2-2479 monoclonal antibody Effective mutant against this position in the RBD for highly neutralizing COV2-2050 monoclonal antibody	False	True	Eta	VOI	active	17-Mar-2021		
MN908947.3	.	23012	23012	p.E484K	c.G1450A	p.E484K	S	S	MISSENSE	3279						9	3269	G	A	B.1.525	monoclonal antibody serial passage escape	Starr et al. (2021) 		Escape mutation against monoclonal antibody LY-CoV555 (antibody that forms the basis for Eli Lilly's bamlanivimab)	False	True	Eta	VOI	active	17-Mar-2021		
MN908947.3	.	23012	23012	p.E484K	c.G1450A	p.E484K	S	S	MISSENSE	3279						9	3269	G	A	B.1.525	monoclonal antibody serial passage escape	Wang et al. (2021) 		Class 2 antibodies C627, C602, C671, C643, and class 2/3 antibody C603 selected for the emergence of the E484K mutation in vitro.	False	True	Eta	VOI	active	17-Mar-2021		
MN908947.3	.	23012	23012	p.E484K	c.G1450A	p.E484K	S	S	MISSENSE	3279						9	3269	G	A	B.1.525	virion structure	Spratt et al. (2021) 		Estimated free energy change (ddG) for this variant is -0.6 kcal/mol (i.e. destabilizing relative to wild type) 	False	True	Eta	VOI	active	17-Mar-2021		
MN908947.3	.	23403	23403	p.D614G	c.A1841G	p.D614G	S	S	MISSENSE	3279						2	3277	A	G	B.1.525	immunosuppression variant emergence	Landis et al. (2021) 		Studying 94 COVID-19 extended infection cases with genomics April 1 to October 17, 2020, one case developed 23 mutations in a 19 day period, including this combination in Spike.	False	True	Eta	VOI	active	17-Mar-2021		
MN908947.3	.	23403	23403	p.D614G	c.A1841G	p.D614G	S	S	MISSENSE	3279						2	3277	A	G	B.1.525	syncytium formation	Kim et al. (2021) 		Slight increase in Vero cell-cell membrane fusion assay under infection with VSV pseudotyped virus.	False	True	Eta	VOI	active	17-Mar-2021		
MN908947.3	.	23403	23403	p.D614G	c.A1841G	p.D614G	S	S	MISSENSE	3279						2	3277	A	G	B.1.525	ACE2 receptor binding affinity	Li et al. (2020) 		In four cell lines (including 293T-hACE2 cells), this mutation combination increases infectivity vs D614G alone	False	True	Eta	VOI	active	17-Mar-2021		
MN908947.3	.	23403	23403	p.D614G	c.A1841G	p.D614G	S	S	MISSENSE	3279						2	3277	A	G	B.1.525	trafficking	Kim et al. (2021) 		~4x more efficient S2 domain cleavage compared to wild type in Caco-2 cells, mid-range of three cell line tested (Vero and Calu-3).	False	True	Eta	VOI	active	17-Mar-2021		
MN908947.3	.	23403	23403	p.D614G	c.A1841G	p.D614G	S	S	MISSENSE	3279						2	3277	A	G	B.1.525	trafficking	Kim et al. (2021) 		No change in infectivity (24h) relative to D614G alone in Caco-2 cells, Vero or Calu-3.	False	True	Eta	VOI	active	17-Mar-2021		
MN908947.3	.	23403	23403	p.D614G	c.A1841G	p.D614G	S	S	MISSENSE	3279						2	3277	A	G	B.1.525	trafficking	Kuzmina et al. (2021) 	'E484K'	~2x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction.	False	True	Eta	VOI	active	17-Mar-2021		
MN908947.3	.	23403	23403	p.D614G	c.A1841G	p.D614G	S	S	MISSENSE	3279						2	3277	A	G	B.1.525	trafficking	Barrett et al. (2021) 		Circulating variant shown in vitro to not have major defects or enhancement of cell surface protein trafficking (i.e. Spike cleavage or fusion required for cell entry)	False	True	Eta	VOI	active	17-Mar-2021		
MN908947.3	.	23403	23403	p.D614G	c.A1841G	p.D614G	S	S	MISSENSE	3279						2	3277	A	G	B.1.525	trafficking	Zhang et l. (2020) 		We report here pseudoviruses carrying SG614 enter ACE2-expressing cells more efficiently than wild type (~9-fold).  This increased entry correlates with less S1-domain shedding and higher S-protein incorporation into the virion.  D614G does not alter S-protein binding to ACE2 or neutralization sensitivity of pseudoviruses. Thus, D614G may  increase infectivity by assembling more functional S protein into the virion.	False	True	Eta	VOI	active	17-Mar-2021		
MN908947.3	.	23403	23403	p.D614G	c.A1841G	p.D614G	S	S	MISSENSE	3279						2	3277	A	G	B.1.525	trafficking	Ozono et al. (2020) 		Among S variants tested, the D614G mutant shows the highest cell entry (~3.5x wild type), as supported by  structural and binding analyses. 	False	True	Eta	VOI	active	17-Mar-2021		
MN908947.3	.	23403	23403	p.D614G	c.A1841G	p.D614G	S	S	MISSENSE	3279						2	3277	A	G	B.1.525	trafficking	Daniloski et al. (2021) 		The increased transduction with Spike D614G ranged from 1.3- to 2.4-fold in Caco-2 and Calu-3 cells expressing  endogenous ACE2 and from 1.5- to 7.7-fold in A549ACE2 and Huh7.5ACE2 overexpressing ACE2.  Although there is minimal difference in ACE2 receptor binding between the D614 and G614 Spike variants,  the G614 variant is more resistant to proteolytic cleavage, suggesting a possible mechanism for the increased transduction.	False	True	Eta	VOI	active	17-Mar-2021		
MN908947.3	.	23403	23403	p.D614G	c.A1841G	p.D614G	S	S	MISSENSE	3279						2	3277	A	G	B.1.525	tissue specific neutralization	Planas et al. (2021) 		The nasal mucosa of Pfizer vaccinees with time course collection was evaluated against VSV pseudotypes: results (only one nasal  swab from different previously infected vacinee neutralizing at weeks 3 and 6 against B.1.1.7 and D614G) suggest that vaccinees probably  do not elicit an early humoral response detectable at mucosal surfaces even though sera neutralization was observed. They strengthen the hypothesis that some vaccines may not protect against  viral acquisition and infection of the oral–nasal region, but may prevent severe disease associated with viral dissemination in the lower respiratory tract. 	False	True	Eta	VOI	active	17-Mar-2021		
MN908947.3	.	23403	23403	p.D614G	c.A1841G	p.D614G	S	S	MISSENSE	3279						2	3277	A	G	B.1.525	viral load	Plante et al. (2020) 		Hamsters infected with SARS-CoV-2 expressing spike(D614G) (G614 virus) produced higher infectious titres in nasal washes and the trachea, but not in the lungs,  supporting clinical evidence showing that the mutation enhances viral loads in the upper respiratory tract of COVID-19 patients and may increase transmission.	False	True	Eta	VOI	active	17-Mar-2021		
MN908947.3	.	23403	23403	p.D614G	c.A1841G	p.D614G	S	S	MISSENSE	3279						2	3277	A	G	B.1.525	convalescent plasma escape	Tada et al. (2021) 	'E484K'	Pseudotyped viruses for B.1.618 was 2.5-fold resistant to neutralization by convalescent sera compared to wild type - a finding that was similar to that of the 3-fold resistance of the South Africa B.1.351 variant using the same assay. The resistance of B.1.618 was caused by the E484K mutation, based on results from viruses pseudotyped for individual variants within B.1.618. [details on the convalescent patient sera collection are not abundantly clear in the preprint]	False	True	Eta	VOI	active	17-Mar-2021		
MN908947.3	.	23403	23403	p.D614G	c.A1841G	p.D614G	S	S	MISSENSE	3279						2	3277	A	G	B.1.525	vaccine neutralization efficacy	Tada et al. (2021) 	'E484K'	Pseudotyped viruses for B.1.618 was 2.7-fold resistant to neutralization by 6 BNT162b2 vaccine sera 28 days post-booster compared to wild type - a finding that was similar to that of the 3.4-fold resistance of the South Africa B.1.351 variant using the same assay. Neutralization by 3 Moderna vaccine sera 28 days post-booster was 3-fold resistant (vs. 2.2-fold for B.1.351). The resistance of B.1.618 was caused by the E484K mutation, based on results from viruses pseudotyped for individual variants within B.1.618.	False	True	Eta	VOI	active	17-Mar-2021		
MN908947.3	.	23403	23403	p.D614G	c.A1841G	p.D614G	S	S	MISSENSE	3279						2	3277	A	G	B.1.525	vaccine neutralization efficacy	Kuzmina et al. (2021) 	'E484K'	This variant showed only minor in Pfizer sera (one or two dose) neutralization efficiency vs D614G (using lentivirus pseudotype).	False	True	Eta	VOI	active	17-Mar-2021		
MN908947.3	.	23403	23403	p.D614G	c.A1841G	p.D614G	S	S	MISSENSE	3279						2	3277	A	G	B.1.525	vaccine neutralization efficacy	Kuzmina et al. (2021) 		Using a lentivirus virus pseudotyped with D614G Spike, sera from vaccinated individuals who received the second dose (9–11 days post-second dose of Pfizer) exhibited a robust  neutralizing potential, with a mean NT50 value of 99,000. This was an average of a 2-fold increase, relative to sera drawn from the  individuals who received one dose of vaccination—mean NT50 dilution of 51,300. Importantly, a 6-fold increase in mean NT50 dilution was  obtained when sera from the first vaccination dose was compared to convalescent sera from cohort with severe disease (NT50 51,000 vs 8,700)  21 to 63 days post-onset. 	False	True	Eta	VOI	active	17-Mar-2021		
MN908947.3	.	23403	23403	p.D614G	c.A1841G	p.D614G	S	S	MISSENSE	3279						2	3277	A	G	B.1.525	vaccine neutralization efficacy	Garcia-Beltran et al. (2021) 		Pseudotyped D614G virus has reduced neutralization activity vs wild type: 1.2x (37 sera Pfizer median 9  days post 2nd dose, 37 sera Moderna median 18 days post 2nd dose). This was NOT significant by ANOVA.	False	True	Eta	VOI	active	17-Mar-2021		
MN908947.3	.	23403	23403	p.D614G	c.A1841G	p.D614G	S	S	MISSENSE	3279						2	3277	A	G	B.1.525	virion structure	Zhang et al. (2020) 		Based on pseudotyped virus experiments, D614G may increase infectivity by assembling more functional S protein into the virion.	False	True	Eta	VOI	active	17-Mar-2021		
MN908947.3	.	23403	23403	p.D614G	c.A1841G	p.D614G	S	S	MISSENSE	3279						2	3277	A	G	B.1.525	virion structure	Yurkovetskiy et al. (2020) 		"CryoEM shows increased proportion of ""one-up"" trimer conformation of Spike proteins on the surface of virions, where the up  conformation is presumed to be more likely to bind ACE2."	False	True	Eta	VOI	active	17-Mar-2021		
MN908947.3	.	23403	23403	p.D614G	c.A1841G	p.D614G	S	S	MISSENSE	3279						2	3277	A	G	B.1.525	virion structure	Weissman et al. (2020) 		"Negative stain EM shows increased proportion of ""one-up"" trimer conformation of Spike proteins on the surface of virions, where the up  conformation is presumed to be more likely to bind ACE2."	False	True	Eta	VOI	active	17-Mar-2021		
MN908947.3	.	23403	23403	p.D614G	c.A1841G	p.D614G	S	S	MISSENSE	3279						2	3277	A	G	B.1.525	virion structure	Spratt et al. (2021) 		Estimated free energy change (ddG) for this variant is 2.5 kcal/mol (i.e. stabilizing relative to wild type) 	False	True	Eta	VOI	active	17-Mar-2021		
MN908947.3	.	23593	23593	p.Q677H	c.G2031C	p.Q677H	S	S	MISSENSE	3279						8	3268	G	C	B.1.525	transmissibility	Albertsen et al. (2021) 		The B.1.525 appears to have poor transmissibility when in competition with B.1.1.7 and other cirdulting strains in Denmark (early 2021).	False	True	Eta	VOI	active	17-Mar-2021		
MN908947.3	.	24224	24224	p.F888L	c.T2662C	p.F888L	S	S	MISSENSE	3279						12	3260	T	C	B.1.525	transmissibility	Albertsen et al. (2021) 		The B.1.525 appears to have poor transmissibility when in competition with B.1.1.7 and other cirdulting strains in Denmark (early 2021).	False	True	Eta	VOI	active	17-Mar-2021		
MN908947.3	.	24748	24748	p.F1062F	c.C3186T	p.F1062F	S	S	SILENT	3279						8	3269	C	T	B.1.525					False	False	Eta	VOI	active	17-Mar-2021		
MN908947.3	.	26305	26305	p.L21F	c.C61T	p.L21F	E	E	MISSENSE	2721						70	2584	C	T	B.1.525					False	True	Eta	VOI	active	17-Mar-2021		
MN908947.3	.	26767	26767	p.I82T	c.T245C	p.I82T	M	M	MISSENSE	3279						2	3276	T	C	B.1.525	homoplasy	Shen et al. (2021) 		This mutation presents mainly within the B.1 (44.0%) and B.1.525 (38.1%) lineages.  Currently, 99.7% of the B.1.525 lineage isolates carry the M:I82T mutation. While this mutation is scattered across multiple  phylogenetic clades, most cases cluster in two recent clades, suggesting a likely selective advantage in certain haplotype backgrounds.	False	True	Eta	VOI	active	17-Mar-2021		
MN908947.3	.	27204	27204	p.F2del	c.4_6delTTT	p.F2del	ORF6	ORF6		3279						3274	3189	GTTT	G	B.1.525					False	False	Eta	VOI	active	17-Mar-2021		
MN908947.3	.	27205	27205	p.F2I	c.T4A	p.F2I	ORF6	ORF6	MISSENSE	86						58	22	T	N	B.1.525					False	False	Eta	VOI	active	17-Mar-2021		
MN908947.3	.	28277	28277	p.S2_D3delinsY	c.5_7delCTG	p.S2_D3delinsY	N	N		3279						3278	3192	TCTG	T	B.1.525					False	False	Eta	VOI	active	17-Mar-2021		
MN908947.3	.	28278	28278	p.S2Y	c.C5A	p.S2Y	N	N	MISSENSE	86						36	30	C	A	B.1.525					False	False	Eta	VOI	active	17-Mar-2021		
MN908947.3	.	28308	28308	p.A12G	c.C35G	p.A12G	N	N	MISSENSE	3279						13	3227	C	G	B.1.525					False	True	Eta	VOI	active	17-Mar-2021		
MN908947.3	.	28699	28699	p.P142P	c.A426G	p.P142P	N	N	SILENT	3279						3	3272	A	G	B.1.525					False	False	Eta	VOI	active	17-Mar-2021		
MN908947.3	.	28887	28887	p.T205I	c.C614T	p.T205I	N	N	MISSENSE	3279						12	3263	C	T	B.1.525					False	True	Eta	VOI	active	17-Mar-2021		
MN908947.3	.	29543	29543	c.G-15T	c.G-15T		ORF10	intergenic		3146						106	3034	G	T	B.1.525					False	False	Eta	VOI	active	17-Mar-2021		
MN908947.3	.	29728	29728	c.T29728N	c.T29728N		intergenic	Stem-loop,3' UTR		1175						650	430	T	N	B.1.525					False	False	Eta	VOI	active	17-Mar-2021		
MN908947.3	.	29729	29729	c.T29729N	c.T29729N		intergenic	Stem-loop,3' UTR		1148						609	529	T	N	B.1.525					False	False	Eta	VOI	active	17-Mar-2021		
MN908947.3	.	29730	29730	c.C29730N	c.C29730N		intergenic	Stem-loop,3' UTR		1146						610	531	C	N	B.1.525					False	False	Eta	VOI	active	17-Mar-2021		
MN908947.3	.	29731	29731	c.A29731N	c.A29731N		intergenic	Stem-loop,3' UTR		1146						611	533	A	N	B.1.525					False	False	Eta	VOI	active	17-Mar-2021		
MN908947.3	.	29732	29732	c.C29732N	c.C29732N		intergenic	Stem-loop,3' UTR		1146						608	535	C	N	B.1.525					False	False	Eta	VOI	active	17-Mar-2021		
MN908947.3	.	29733	29733	c.C29733N	c.C29733N		intergenic	Stem-loop,3' UTR		1146						606	538	C	N	B.1.525					False	False	Eta	VOI	active	17-Mar-2021		
MN908947.3	.	29734	29734	c.G29734N	c.G29734N		intergenic	Stem-loop,3' UTR		1146						606	538	G	N	B.1.525					False	False	Eta	VOI	active	17-Mar-2021		
MN908947.3	.	29735	29735	c.A29735N	c.A29735N		intergenic	Stem-loop,3' UTR		1146						607	538	A	N	B.1.525					False	False	Eta	VOI	active	17-Mar-2021		
MN908947.3	.	29736	29736	c.G29736N	c.G29736N		intergenic	Stem-loop,3' UTR		1146						607	538	G	N	B.1.525					False	False	Eta	VOI	active	17-Mar-2021		
MN908947.3	.	29737	29737	c.G29737N	c.G29737N		intergenic	Stem-loop,3' UTR		1147						607	536	G	N	B.1.525					False	False	Eta	VOI	active	17-Mar-2021		
MN908947.3	.	29738	29738	c.C29738N	c.C29738N		intergenic	Stem-loop,3' UTR		1146						610	536	C	N	B.1.525					False	False	Eta	VOI	active	17-Mar-2021		
MN908947.3	.	29739	29739	c.C29739N	c.C29739N		intergenic	Stem-loop,3' UTR		1152						613	538	C	N	B.1.525					False	False	Eta	VOI	active	17-Mar-2021		
MN908947.3	.	29740	29740	c.A29740N	c.A29740N		intergenic	Stem-loop,3' UTR		1152						608	544	A	N	B.1.525					False	False	Eta	VOI	active	17-Mar-2021		
MN908947.3	.	29741	29741	c.C29741N	c.C29741N		intergenic	Stem-loop,3' UTR		1152						608	544	C	N	B.1.525					False	False	Eta	VOI	active	17-Mar-2021		
MN908947.3	.	29742	29742	c.G29742N	c.G29742N		intergenic	Stem-loop,3' UTR		1137						582	544	G	N	B.1.525					False	False	Eta	VOI	active	17-Mar-2021		
MN908947.3	.	29743	29743	c.C29743N	c.C29743N		intergenic	Stem-loop,3' UTR		1137						589	548	C	N	B.1.525					False	False	Eta	VOI	active	17-Mar-2021		
MN908947.3	.	29744	29744	c.G29744N	c.G29744N		intergenic	Stem-loop,3' UTR		1137						587	549	G	N	B.1.525					False	False	Eta	VOI	active	17-Mar-2021		
MN908947.3	.	29745	29745	c.G29745N	c.G29745N		intergenic	Stem-loop,3' UTR		1136						587	549	G	N	B.1.525					False	False	Eta	VOI	active	17-Mar-2021		
MN908947.3	.	29746	29746	c.A29746N	c.A29746N		intergenic	Stem-loop,3' UTR		1136						586	549	A	N	B.1.525					False	False	Eta	VOI	active	17-Mar-2021		
MN908947.3	.	29747	29747	c.G29747N	c.G29747N		intergenic	Stem-loop,3' UTR		1136						588	547	G	N	B.1.525					False	False	Eta	VOI	active	17-Mar-2021		
MN908947.3	.	29748	29748	c.T29748N	c.T29748N		intergenic	Stem-loop,3' UTR		1136						589	547	T	N	B.1.525					False	False	Eta	VOI	active	17-Mar-2021		
MN908947.3	.	29749	29749	c.A29749N	c.A29749N		intergenic	Stem-loop,3' UTR		1136						589	547	A	N	B.1.525					False	False	Eta	VOI	active	17-Mar-2021		
MN908947.3	.	29750	29750	c.C29750N	c.C29750N		intergenic	Stem-loop,3' UTR		1136						586	547	C	N	B.1.525					False	False	Eta	VOI	active	17-Mar-2021		
MN908947.3	.	29751	29751	c.G29751N	c.G29751N		intergenic	Stem-loop,3' UTR		1136						589	547	G	N	B.1.525					False	False	Eta	VOI	active	17-Mar-2021		
MN908947.3	.	29752	29752	c.A29752N	c.A29752N		intergenic	Stem-loop,3' UTR		1136						588	548	A	N	B.1.525					False	False	Eta	VOI	active	17-Mar-2021		
MN908947.3	.	29753	29753	c.T29753N	c.T29753N		intergenic	Stem-loop,3' UTR		1134						584	549	T	N	B.1.525					False	False	Eta	VOI	active	17-Mar-2021		
MN908947.3	.	29754	29754	c.C29754N	c.C29754N		intergenic	Stem-loop,3' UTR		1134						583	551	C	N	B.1.525					False	False	Eta	VOI	active	17-Mar-2021		
MN908947.3	.	29755	29755	c.G29755N	c.G29755N		intergenic	Stem-loop,3' UTR		1134						583	551	G	N	B.1.525					False	False	Eta	VOI	active	17-Mar-2021		
MN908947.3	.	29756	29756	c.A29756N	c.A29756N		intergenic	Stem-loop,3' UTR		1134						582	552	A	N	B.1.525					False	False	Eta	VOI	active	17-Mar-2021		
MN908947.3	.	29757	29757	c.G29757N	c.G29757N		intergenic	Stem-loop,3' UTR		1134						583	551	G	N	B.1.525					False	False	Eta	VOI	active	17-Mar-2021		
MN908947.3	.	29758	29758	c.T29758N	c.T29758N		intergenic	Stem-loop,3' UTR		1134						583	550	T	N	B.1.525					False	False	Eta	VOI	active	17-Mar-2021		
MN908947.3	.	29759	29759	c.G29759N	c.G29759N		intergenic	Stem-loop,3' UTR		1134						584	550	G	N	B.1.525					False	False	Eta	VOI	active	17-Mar-2021		
MN908947.3	.	29760	29760	c.T29760N	c.T29760N		intergenic	Stem-loop,3' UTR		1134						584	550	T	N	B.1.525					False	False	Eta	VOI	active	17-Mar-2021		
MN908947.3	.	29761	29761	c.A29761N	c.A29761N		intergenic	Stem-loop,3' UTR		1134						583	551	A	N	B.1.525					False	False	Eta	VOI	active	17-Mar-2021		
MN908947.3	.	29762	29762	c.C29762N	c.C29762N		intergenic	Stem-loop,3' UTR		1134						584	550	C	N	B.1.525					False	False	Eta	VOI	active	17-Mar-2021		
MN908947.3	.	29763	29763	c.A29763N	c.A29763N		intergenic	Stem-loop,3' UTR		1133						589	544	A	N	B.1.525					False	False	Eta	VOI	active	17-Mar-2021		
MN908947.3	.	29764	29764	c.G29764N	c.G29764N		intergenic	Stem-loop,3' UTR		1134						590	544	G	N	B.1.525					False	False	Eta	VOI	active	17-Mar-2021		
MN908947.3	.	29765	29765	c.T29765N	c.T29765N		intergenic	Stem-loop,3' UTR		1134						589	545	T	N	B.1.525					False	False	Eta	VOI	active	17-Mar-2021		
MN908947.3	.	29766	29766	c.G29766N	c.G29766N		intergenic	Stem-loop,3' UTR		1134						590	544	G	N	B.1.525					False	False	Eta	VOI	active	17-Mar-2021		
MN908947.3	.	29767	29767	c.A29767N	c.A29767N		intergenic	Stem-loop,3' UTR		1134						589	545	A	N	B.1.525					False	False	Eta	VOI	active	17-Mar-2021		
MN908947.3	.	29768	29768	c.A29768N	c.A29768N		intergenic	Stem-loop,3' UTR		1115						569	546	A	N	B.1.525					False	False	Eta	VOI	active	17-Mar-2021		
MN908947.3	.	29769	29769	c.C29769N	c.C29769N		intergenic	3' UTR		1109						563	544	C	N	B.1.525					False	False	Eta	VOI	active	17-Mar-2021		
MN908947.3	.	29770	29770	c.A29770N	c.A29770N		intergenic	3' UTR		1109						565	544	A	N	B.1.525					False	False	Eta	VOI	active	17-Mar-2021		
MN908947.3	.	29771	29771	c.A29771N	c.A29771N		intergenic	3' UTR		1109						563	546	A	N	B.1.525					False	False	Eta	VOI	active	17-Mar-2021		
MN908947.3	.	29772	29772	c.T29772N	c.T29772N		intergenic	3' UTR		1109						565	544	T	N	B.1.525					False	False	Eta	VOI	active	17-Mar-2021		
MN908947.3	.	29773	29773	c.G29773N	c.G29773N		intergenic	3' UTR		1109						566	542	G	N	B.1.525					False	False	Eta	VOI	active	17-Mar-2021		
MN908947.3	.	29774	29774	c.C29774N	c.C29774N		intergenic	3' UTR		1109						565	539	C	N	B.1.525					False	False	Eta	VOI	active	17-Mar-2021		
MN908947.3	.	29775	29775	c.T29775N	c.T29775N		intergenic	3' UTR		1109						638	471	T	N	B.1.525					False	False	Eta	VOI	active	17-Mar-2021		
MN908947.3	.	29776	29776	c.A29776N	c.A29776N		intergenic	3' UTR		1109						576	451	A	N	B.1.525					False	False	Eta	VOI	active	17-Mar-2021		
MN908947.3	.	29862	29862	c.G29862N	c.G29862N		intergenic	3' UTR		427						292	134	G	N	B.1.525					False	False	Eta	VOI	active	17-Mar-2021		
MN908947.3	.	29863	29863	c.A29863N	c.A29863N		intergenic	3' UTR		404						244	159	A	N	B.1.525					False	False	Eta	VOI	active	17-Mar-2021		
MN908947.3	.	29864	29864	c.G29864N	c.G29864N		intergenic	3' UTR		396						239	156	G	N	B.1.525					False	False	Eta	VOI	active	17-Mar-2021		
MN908947.3	.	29865	29865	c.A29865N	c.A29865N		intergenic	3' UTR		376						214	162	A	N	B.1.525					False	False	Eta	VOI	active	17-Mar-2021		
MN908947.3	.	29866	29866	c.A29866N	c.A29866N		intergenic	3' UTR		374						221	153	A	N	B.1.525					False	False	Eta	VOI	active	17-Mar-2021		
MN908947.3	.	29867	29867	c.T29867N	c.T29867N		intergenic	3' UTR		367						215	152	T	N	B.1.525					False	False	Eta	VOI	active	17-Mar-2021		
MN908947.3	.	29868	29868	c.G29868N	c.G29868N		intergenic	3' UTR		366						265	101	G	N	B.1.525					False	False	Eta	VOI	active	17-Mar-2021		
